IMDX
Insight Molecular Diagnostics Inc.
$4.82
+0.36 (+8.07%)
At close · Jul 15
Market Cap
$155.64M
Shares
32,290,167
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$4.06M
+115.6%
FY2025
Net Income
-$50.22M
+17.2%
FY2025
Gross Margin
56.67%
+17.3pp
FY2025
Operating Margin
-1260.76%
+1984.4pp
FY2025
Diluted EPS
-$1.65
+64.6%
FY2025
Operating Cash Flow
-$22.18M
-7.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.95M | $4.06M | $1.88M | $1.5M | $958K | $7.73M | $1.22M | — | — | — | — | |
| -$103K | -$109K | -$84K | -$52K | -$77K | -$209K | -$252K | $299K | -$216K | — | -$28K | |
| $954K | $1.75M | $1.05M | $1M | $880K | $4.19M | $1.86M | — | — | — | — | |
| $988K | $2.3M | $740K | $413K | -$18K | $188K | — | — | — | — | — | |
| — | 56.67% | 39.34% | 27.48% | -1.88% | 2.43% | — | — | — | — | — | |
| $17.93M | $15.9M | $9.84M | $9.29M | $7.3M | $13.63M | $9.8M | $6.79M | $6.51M | $7.17M | $5.68M | |
| $7.54M | $6.34M | $3.94M | $2.8M | $1.13M | $11.17M | $6.49M | $2.16M | $1.68M | $2.44M | — | |
| $10.51M | $10.63M | $10.2M | $11.18M | $21.88M | $22.34M | $16.79M | $13.28M | $7.01M | $9.23M | $5.46M | |
| $0 | $7000 | $88K | $88K | $3.69M | $3.36M | $81K | $121K | $121K | $242K | $242K | |
| $2.34M | $2.2M | $1.56M | $1.59M | $1.5M | $844K | — | — | — | — | — | |
| $49.73M | $53.42M | $61.78M | $25.55M | $17.98M | $74.4M | — | $22.24M | $15.2M | $18.85M | $11.14M | |
| -$48.74M | -$51.12M | -$61.04M | -$25.14M | -$18M | -$74.21M | -$29.71M | -$22.24M | -$15.2M | -$18.85M | -$11.14M | |
| — | -1260.76% | -3245.14% | -1672.39% | -1878.6% | -960.42% | -2443.34% | — | — | — | — | |
| -$46.4M | -$48.93M | -$59.48M | -$23.54M | -$16.5M | -$73.37M | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | $0 | |
| $897K | $902K | $378K | $281K | -$615K | $854K | -$1.48M | -$187K | -$552K | -$526K | -$28K | |
| — | — | — | — | -$270K | -$270K | -$1.55M | -$281K | — | — | — | |
| — | — | -$60.66M | -$24.86M | -$18.61M | -$73.36M | -$31.19M | — | — | — | — | |
| $0 | $0 | $0 | — | -$9.26M | -$9.26M | -$1.25M | — | — | — | — | |
| -$47.84M | -$50.22M | -$60.66M | -$27.78M | -$72.9M | -$64.1M | -$29.93M | -$22.43M | -$15.75M | -$19.38M | -$11.17M | |
| — | -1238.52% | -3225.04% | -1848.37% | -7609.81% | -829.52% | -2461.51% | — | — | — | — | |
| — | -$50.22M | -$60.93M | -$28.72M | -$73.42M | — | — | — | — | — | — | |
| -$47.81M | -$50.16M | -$60.69M | -$27.77M | -$72.9M | -$64.06M | -$29.93M | -$22.43M | -$15.75M | -$19.61M | -$11.47M | |
| USD/shares | — | -$1.65 | -$4.66 | -$3.75 | -$13.20 | — | — | — | — | — | — |
| USD/shares | — | -$1.65 | -$4.66 | -$3.75 | — | — | — | — | — | — | — |
| shares | — | 30.48M | 13.07M | 7.65M | 5540 | 4446 | 3.27M | 2.56M | 1.89M | 1.51M | 1.33M |
| shares | — | 30.48M | 13.07M | 7.65M | — | 4446 | 3.27M | 2.56M | 1.89M | 1.51M | 1.33M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Diagnostics & Research median 2.91×
EV/EBIT
—
Diagnostics & Research median 31.28×
P/E (TTM)
—
Diagnostics & Research median 32.34×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| United States | $4,031,000 | $1,673,000 | $923,000 |
| Europe | $24,000 | $18,000 | — |
| United Kingdom | $0 | $45,000 | $409,000 |
| Asia Pacific | $0 | $145,000 | $160,000 |
| Spain | — | — | $11,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Laboratory Services | $4,031,000 | $1,859,000 | — |
| Kitted Products | $24,000 | $0 | — |
| Laboratory Developed Test Services | $0 | $22,000 | — |
| Laboratory Developed Test Services | — | — | $36,000 |
| Pharma Services | — | — | $1,467,000 |